Abcam, a Danaher company and a global provider of validated antibodies and assay solutions, today announced SimpleStep Ignite ELISA, a next-generation chemiluminescent immunoassay platform designed for scientists who need faster and higher quality decisions without compromising data integrity.
Delivering results in 55 minutes - up to 6× faster than traditional colourimetric ELISAs, SimpleStep Ignite combines 50× greater sensitivity with an up to 35× broader measuring range to quantify low abundance and high abundance targets in a single, streamlined workflow.
In an environment where research timelines are tight and sample volumes are precious, assay performance has become a critical rate-limiting step. SimpleStep Ignite ELISA is built to help scientists increase daily data output, reduce reruns, and move from results to decision faster with robust sensitivity, a wide dynamic range, and reproducibility that supports confident decision-making across discovery and preclinical workflows.
"The pace of scientific progress is increasingly defined by how quickly researchers can turn complex data into confident decisions. At Abcam, we believe advancing science means removing the barriers that slow discovery as ambition and complexity grow. SimpleStep Ignite reflects that belief, bringing together speed, performance, and scalable simplicity to help scientists generate trusted insights faster and sustain momentum in pursuit of the questions that matter most." Markus Lusser, President, Abcam
SimpleStep Ignite combines chemiluminescent detection with Abcam's optimised SimpleStep technology to deliver a stronger signal, lower background, and consistent quantification, without additional workflow complexity. Each kit is built using optimised antibody pairs to support consistent batch-to-batch performance and reproducible results across complex biological matrices, including serum, plasma, urine, cerebrospinal fluid (CSF), and more.
With fewer incubations and a simple single wash protocol, researchers can quantify both high and low-abundance targets with the same kit, reducing repeat work, extra dilutions, and sample consumption. The standardised workflow supports plate-by-plate studies as well as higher throughput screening, enabling teams to scale data generation without sacrificing quality.
